*Prices reflect U.S. average retail price

The drug combination atorvastatin/amlodipine (trade names Caduet in the US, Australia and Russia, and Envacar elsewhere) is a medication approved by the Food and Drug Administration (FDA) for the treatment of high cholesterol and high blood pressure. It is a fixed-dose combination drug containing the calcium channel blocker amlodipine and the statin atorvastatin being marketed by the pharmaceutical company Pfizer... Wikipedia

Manufacturer's Website: Caduet                                                                                                                      Average retail cost: $607/month

Ezetimibe is a drug that lowers plasma cholesterol levels. It acts by decreasing cholesterol absorption in the small intestine. It may be used alone (marketed as Zetia or Ezetrol), when other cholesterol-lowering medications are not tolerated, or together with statins (e.g., ezetimibe/simvastatin, marketed as Vytorin or Inegy) when statins alone do not control cholesterol... Wikipedia

Manufacturer's Website: Lipitruzet                                                                                                                     Average retail cost: $1,359/month

Niacin/simvastatin (trade name Simcor, by Abbott) is a combination drug consisting of an extended release form of the vitamin niacin and the statin drug simvastatin. It is used for the treatment of dyslipidemia. It was approved by the FDA on February 15, 2008. On April 15, 2016, the FDA pulled the approval of niacin and fibrates used in combination with statin drugs, citing growing evidence that the benefits of combining niacin or fibrate drugs with statin drugs to not outweigh the risks, compared to statin therapy alone....Wikipedia

Simcor is no longer manufactured.

Niacin/lovastatin (trade names Advicor, Mevacor) is a drug combination used for the treatment of dyslipidemia. It is a combination of the vitamin niacin and the statin drug lovastatin....Wikipedia

Advicor is no longer manufactured.

Simvastatin/sitagliptin (brand name Juvisync) is a fixed-dose combination drug consisting of sitagliptin and simvastatin. Sitagliptin is a dipeptidyl peptidase-4 inhibitor used to treat type 2 diabetes and simvastatin is an HMG-CoA reductase inhibitor used to treat hypercholesterolemia. These two disorders commonly occur in patients at the same time, and have been typically treated with administration of these two drugs in separate tablets. The combination was approved in 2011 and is marketed as Juvisync by Merck. Juvisync was later removed from the market in 2013 due to business reasons....Wikipedia

Juvisync is no longer manufactured.